Background illustration for clinical trials search

Vaccines Clinical Trials

Find clinical trials for vaccines. Search for vaccines clinical trials in different cities and states across the United States.

Filter
New

A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

for
Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer,
Location: Quebec, Montreal, Richmond VA, Salem OR
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07827573

Phase 3, Recruiting
New

CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

for
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M),
Location: Fairfax VA, Dallas TX, Austin TX
Sponsor: Crescent Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07909031

Phase 1, Phase 2, Recruiting
New

Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy

for
Breast Cancer,
Location: Stony Brook NY
Sponsor: Josephine Connolly-Schoonen

Sex: Female

Age: 18 - 70+

Code: NCT07897344

Recruiting
New

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

for
Head and Neck Cancer, Head and Neck Squamous Cell Cancer,
Location: Glen Burnie MD, Baltimore MD, Columbia MD
Sponsor: University of Maryland, Baltimore

Sex: All

Age: 18+

Code: NCT07418034

Phase 2, Recruiting
New

A Study of Skipping Radiation Therapy in People With Breast Cancer

for
HER2-positive Breast Cancer, Breast Cancer
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07895511

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
New

Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study

for
Vulvar Intraepithelial Neoplasia, HPV-Independent,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT07886203

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for
Hormone Receptor Positive HER-2 Negative Breast Cancer,
Location: Boston MA, Horsham PA, Philadelphia PA, Richmond VA,
Sponsor: Puma Biotechnology, Inc.

Sex: All

Age: 18+

Code: NCT06369285

Phase 2, Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

for
Advanced Solid Tumor, Metastatic Solid Tumor,
Location: New York NY, Jacksonville FL, Cleveland OH,
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT05824975

Phase 1, Phase 2, Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for
HER2-positive Gastric Cancer,
Location: Chicoutimi, New York NY, Albany NY, Summit NJ, Montreal,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06764875

Phase 3, Recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,
Location: St Louis MO, Rochester MN, Westwood KS
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06374459

Phase 1, Phase 2, Recruiting

PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer

for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06914999

Early Phase 1, Recruiting

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

for
Hormone Receptor-Positive Breast Cancer,
Location: Long Branch NJ, Elizabeth NJ, Newark NJ, Livingston NJ,
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT06518837

Phase 2, Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

for
HER2-positive Breast Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05325632

Phase 2, Recruiting

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

for
Influenza, Human
Location: Philadelphia PA
Sponsor: University of Pennsylvania

Sex: All

Age: 18+

Code: NCT05108818

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

for
HR+/HER2-negative Breast Cancer
Location: Boston MA, Calverton MD, Roanoke VA, Nashville TN,
Sponsor: Totus Medicines

Sex: Female

Age: 18+

Code: NCT05683418

Phase 1, Recruiting

Screening Strategies Among High-risk Populations for Anal Cancer

for
Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Location: Miami FL, Atlanta GA
Sponsor: Lisa Flowers

Sex: All

Age: 30 - 70+

Code: NCT06628570

Recruiting

HPV Prevalence in 16-20 Year Old Males

for
HPV Infection
Location: Quebec
Sponsor: Laval University

Sex: Male

Age: 16 - 20

Code: NCT04297670

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for
Solid Tumor, Adult, Metastatic Breast Cancer,
Location: Boston MA, New York NY, Tampa FL, Indianapolis IN,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06625775

Phase 1, Recruiting

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

for
HER2-positive Breast Cancer, LMD
Location: Ottawa, Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: All

Age: 18+

Code: NCT06016387

Phase 2, Recruiting

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

for
Estrogen Receptor-Positive, HER2-Negative,
Location: Seattle WA
Sponsor: EnhancedBio USA Inc.

Sex: All

Age: 18+

Code: NCT04669587

Phase 1, Phase 2, Recruiting

What vaccine clinical trials are studying now

New flu vaccines. Moderna's mFlusiva, approved August 5, 2026 for adults 50 and older, is the first mRNA flu vaccine. In its Phase 3 trial it prevented about 27 percent more flu cases than a standard dose vaccine, with more short term side effects. Flu vaccine studies, including human challenge trials, are listed on our influenza clinical trials page.

Vaccines in pregnancy. Vaccinating a mother so antibodies pass to the baby is one of the most active areas of research. A Phase 3 trial of a group B streptococcus vaccine, a leading cause of serious infection in newborns, is recruiting pregnant participants at 120 US sites.

Pneumococcal and other bacterial vaccines. Next generation vaccines that cover more strains of the bacteria behind pneumonia and meningitis, tested against the vaccines in use today. Two pneumococcal vaccine studies are enrolling healthy adults 18 to 75 who have never had a pneumococcal vaccine.

RSV vaccines. Combination and revaccination studies, covered on our RSV vaccine clinical trials page. Studies of new flu and RSV vaccines for adults 60 and older are enrolling now.

Cancer vaccines. These do not prevent cancer; they teach the immune system to attack a cancer that is already there. Intismeran, made for each patient from up to 34 mutations in their own tumor, met its main goal in a Phase 3 melanoma trial in August 2026 but is not yet approved. Smaller studies test vaccines for HER2 positive breast cancer, liver cancer, and HPV related cancers; see our melanoma and breast cancer pages.

COVID-19. Updated formulas are approved each season; the 2026 to 2027 mRNA formula is approved for adults 65 and older and for people 5 to 64 with a condition that raises their risk. One study is testing a COVID-19 vaccine given during an active infection, for people 12 and older who tested positive within the past 5 days and have a risk factor for severe illness; it measures the immune response and is not a treatment for the current illness. Studies of COVID-19 and long COVID are on our COVID-19 page.

Vaccines for infections that have none yet. There is still no approved vaccine against Epstein-Barr virus, the cause of mono, or against C. difficile, a common hospital infection. A study of an EBV vaccine is enrolling healthy adults 18 to 30, and C. diff vaccine studies are enrolling adults 65 and older who have frequent contact with healthcare but have never had the infection.

Human challenge studies. Healthy adults receive a vaccine or placebo, then a controlled dose of a virus such as influenza, in a monitored setting. They answer in weeks what field trials take seasons to show.

Article preview image

65 or older? Read our guide: Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

How vaccine trials differ from drug trials

Who can participate in vaccine clinical trials?

Do vaccine trial participants get paid?

How to enroll in a vaccine clinical trial